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Abstract 
The rate at which agile software development practices are being adopted is growing rapidly. Agile 
software development practices and methodologies appear to offer the silver bullet which can solve 
the problems associated with following plan driven software development lifecycles. Agile software 
development practices offer the possibility of achieving lower development costs, increased efficiency 
and improved software quality. However, there is currently a low rate of publicly available information 
that suggests there is widespread adoption of agile practices within the medical device software do-
main. This is largely due to the fact that software developed for medical devices includes challenges 
not faced when developing non safety critical software. As a result of these challenges, medical device 
software is typically developed using plan driven software development lifecycles. However, such 
lifecycles are quite rigid and cannot accommodate changes easily. Previous research has revealed 
that medical device software development projects can benefit from adopting agile practices whilst still 
maintaining the discipline associated with following plan driven development lifecycles. This paper 
outlines the challenges faced by developers when developing medical device software and how short-
comings in both agile and plan driven approaches can be resolved by following a mixed method ap-
proach to medical device software development.  
Keywords  
Medical Device, Agile, Plan Driven, SDLC, XP, Scrum, V-Model, TDD, FDA, MDD, 
2007/47/EC, Software Process Improvement 
1 Introduction 
Software developers are under increasing pressure to develop software faster that not only meets 
a customer’s requirements, but exceeds them [1]. Initially, iterative software development appeared to 
offer a solution by aiding faster development of systems. Iterative techniques evolved and a subset 
known as agile appeared [2]. Larmin and Basili [3] identified Dynamic Systems Development Model 
(DSDM) as being the first agile methodology. Each of the agile methodologies consists of a number of 
agile practices. These practices are procedures defined as being highly effective and efficient [4] such 
as  sprint planning, an open office space, daily meetings and from Scrum,  product backlogs [5]. The  
use of agile methodologies such as XP and Scrum, in traditional software development projects are 
becoming increasingly popular [6].  
In some case studies, agile practices have been used in the safety critical field. For instance, in 
Motorola, a select number of XP practices were used during the development of  safety critical sys-
tems [7]. In these cases, the use of XP practices was reported to have had a 53% improvement in 
average quality compared to the plan-driven software development projects. A key challenge in these 
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XP projects was to define how the changes affected the overall end date of the projects. Additionally, 
Drobka et al.[7] discusses the issue of documentation production. In the case of Grenning [8], the 
source code was not sufficiently documented for the whole system, and this resulted in the need for a 
high-level architecture document which provided class diagrams, scenarios and a process view of the 
system for developers. Furthermore, acceptance tests were not adequate to verify the traceability from 
end product to customer requirements. Therefore, additional verification review meetings were used to 
cover this gap in the verification process [7]. Grenning [8] describes how XP practices such as the 
planning games, small releases, simple design, test first development; refactoring, pair programming, 
collective ownership, continuous integration and 40 hour week are used in a large company develop-
ing safety critical systems. As a result of this analysis, he suggests that some XP practices, such as 
simple designs integrated with test first development and refactoring work quite well in the safety criti-
cal area. In that case, the managers were reported to be happy with the results of the use of XP prac-
tices. This was mainly due to the XP team’s ability to readily produce working software instead of a 
high amount of documentation [8]. One of the biggest challenges revealed from this case was that 
resistance was caused mainly due to the decreased amount documentation. This documentation was 
needed, for example, to define product requirements, sustain technical reviews, support maintenance 
and describe interfaces. Based on the experiences of the XP projects it was still understood that the 
documentation was needed for maintenance and review purposes [8]. 
In spite of these experiences of adopting agile practices in the safety critical domain, there is still lit-
tle evidence of agile practices being widely embraced when developing medical device software [9]. 
The reason for this is still unclear, but one potential reason is that safety critical systems must also 
meet the appropriate regulatory requirements [10]. As part of the Food and Drug Administration (FDA) 
regulations most items require formal approval and this is cited as being a reason why many medical 
device software developers follow a sequential software development model such as the Waterfall or 
V-Model [11]. Of the limited information available, medical device software projects can benefit from 
incorporating agile practices, but no single agile methodology can be followed when developing medi-
cal device software [12]. 
It is generally perceived that international medical device regulatory requirements recommend that 
software developed either as a component of a medical device or as a medical device should be de-
veloped in accordance with a plan driven software development lifecycle such as the Waterfall Model 
or the V-Model. However, the regulatory requirements and development standards do not enforce the 
usage of any particular software development lifecycle. Whilst no specific software development 
lifecycle is mandated by the regulations or standards medical device software developers typically 
develop software in accordance with the V-Model [13]. Following the V-Model produces the necessary 
deliverables required in order to achieve regulatory approval. The objective of this research is to de-
velop a Software Development Life Cycle (SDLC) that accrues the benefits of utilising agile practices 
whilst still producing the necessary deliverables provided by following plan driven software develop-
ment lifecycles. This paper will serve as the foundation for this research. The remainder of this paper 
will be structured as follows. 
In section 2, the latest regulatory requirements which medical device software organisations must 
adhere to are outlined. In section 3, information is provided as to how regulatory bodies do not require 
the usage of a specific software development lifecycle and that regulatory bodies are only concerned 
with the specific requirements such as traceability rather than being concerned with how these re-
quirements are fulfilled. In section 4, a mixed method software development lifecycle is proposed that 
incorporates agile practices with a plan driven lifecycle and finally in section 5, the conclusions and 
plans for future work are presented. 
2 International Regulations 
Medical device software developers must adhere to the regulatory requirements of the region in 
which a medical device is being marketed for use. Medical devices being marketed for use within the 
United States (US) must conform to the FDA requirements and medical devices being marketed for 
use within the European Union (EU) must conform to the Medical Device Directive (MDD) and its lat-
est amendment. 
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2.1 European Medical Device Directive 
On March 21st 2010 the latest amendment to the MDD 2007/47/EC came into effect [14]. As stated, 
conformance to the latest amendment to the MDD is mandatory for a medical device to be marketed 
for use in the EU. Competent Authorities and notified bodies within each EU member state are re-
sponsible for certifying medical device conformance with the MDD. Once a device is certified within an 
EU member state the device can be marketed into all of the member states. 
The latest amendment to the MDD introduced a number of changes; the most significant with re-
gards to software development is that standalone software can now be classified as an active medical 
device. Prior to this amendment software was considered a component of a hardware medical device. 
With the release of this amendment software can now potentially be the only component of a medical 
device and therefore subject to full regulatory scrutiny. With this change a greater emphasis falls onto 
the international standards which are followed during the development of medical device software. IEC 
62304:2006 [15] is a harmonised standard as part of the MDD [16].  Medical device software develop-
ers are recommended to follow IEC 62304 and its aligned standards to receive guidance. However, 
these aligned standards can be difficult to follow and this is particularly relevant when a medical de-
vice only consists of software. 
2.2 FDA Regulations 
Within the US the FDA is responsible for ensuring medical devices certified for use are safe and re-
liable. The FDA provides guidance documents which medical device software developers are recom-
mended to follow in order to achieve regulatory conformance. These documents include:  
• General Principles of Software Validation (GPSV) [17]; 
• Medical Device Data Systems Rule [18]; 
• Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices 
[19]; 
• Draft Guidance for Industry and Food and Drug Administration - Mobile Device Applications [20]; 
• Guidance for Industry, FDA Reviewers and Compliance on Off-The-Shelf Software use in Medical 
Devices [21]. 
All medical device manufacturers wishing to achieve FDA approval must conform to FDA 21 CFR 
Part 820 Quality System Regulations (QSR) [22]. FDA 21 CFR Part 820 requires medical device 
manufacturers to provide sufficient evidence that a Quality Management System (QMS) was em-
ployed when developing a medical device. To accompany, this all medical device manufacturers 
wishing to achieve FDA approval must follow FDA General Controls [23]. These controls include pro-
visions that relate to device registration, branding and banned devices. 
3 Agile Practices in the Development of Medical Device Software 
When exploring possible frameworks for developing medical device software, we discovered that 
developers in this domain often select a plan driven lifecycle  such as the V-Model [24], rather than  
considering following agile practices with iterative or incremental development lifecycle. This may be 
due to the fact that the agile manifesto places greater emphasis on people rather than processes and 
also considers documentation as being a secondary output from a software development project [25]. 
In practice, formal communication, such as source code, test cases, and essential amount of documenta-
tion is also used in the agile software development, but not in the same way or to the same extent as 
in the plan-driven software development process [26]. Additionally, some of the agile principles sug-
gest that business people and developers must work together daily and project information should be 
shared through informal, face-to-face conversation rather than through documentation [27]. 
However, regulatory bodies in both the US and Europe require medical device manufacturers to 
provide documentation which provides information on areas such as risk and hazard management and 
traceability between the requirements stage and the development stages of a software development 
project [28, 29]. While this is the case, both the FDA guidelines and the MDD do not mandate the use 
of a specific life cycle model. The FDA states: 
“(the FDA) does not recommend the use of any specific software life cycle model. Software developers 
should establish a software life cycle model that is appropriate for their product and organization” 
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To accompany this the FDA also states that the selected life cycle model “should cover the software 
from its birth to its retirement”, and also that the lifecycle model should support validation and verifica-
tion [17]. As discussed medical device software development organisations are recommended to fol-
low IEC 62304 when developing medical device software. IEC 62034 states:  
“The (IEC 62304) standard does not require a particular software development life cycle model” 
To accompany this IEC 62304 also states; 
“Whichever life cycle is chosen it is necessary to maintain the logical dependencies between 
process outputs” 
IEC 62304 does not mandate the use of a specific lifecycle and is more concerned with the regulatory 
requirements such as traceability and not with how these requirements are fulfilled. Both the FDA 
GPSV guidance document and the IEC 62034 standard discuss the use of different life cycle models 
including the waterfall, incremental and evolutionary models. The FDA GPSV states: 
“Most software development models will be iterative. This is likely to result in several versions 
of both the software requirement specification and the software design specification” 
Currently, the Association of Advancement of Medical Instrumentation (AAMI) (the publishers of IEC 
62304) is in the process of completing a technical information report which will provide recommenda-
tions as to how medical device software development organisations can comply with international and 
FDA regulations by using agile practices [30]. This document will provide a complete mapping be-
tween the 12 agile principles [31] and each of the development stages of IEC 62304. All of this infor-
mation signals that regulatory bodies acknowledge that following a plan driven software development 
lifecycle is not always feasible and that agile practices can be used in compliance with IEC 62304 
without jeopardising the process of achieving regulatory approval. 
 A number of case studies have been performed in organisations that are actively utilising agile 
practices in the development of medical device software [12, 32-34]. A common trend emerged out of 
these case studies that medical device software development organisations recognised it was not 
possible to fully replace the existing lifecycle with a single agile methodology, but rather they integrat-
ed agile practices with the plan driven development lifecycle. Heeager and Nielsen [32] recommend 
wrapping the traditional lifecycle in a Scrum approach [35]. Likewise, Robres [36] explored the suitabil-
ity of using Scrum to develop medical device software when attempting to achieve regulatory con-
formance. In these case, the benefits to be achieved when using agile practices to develop medical 
device software reflect those achieved when using agile practices in any software development pro-
ject, they include, reduced development time, reduced costs and increased productivity [37].  
4 Proposed Mixed Method SDLC 
It is well established that tailoring a SDLC should be done in order to achieve maximum impact [6].  
As part of this research we are focusing on integrating agile practices with a plan driven lifecycle. The 
aim of tailoring a plan driven lifecycle with agile practices is to develop a SDLC which produces the 
necessary output required for regulatory approval whilst also reaping the benefits associated with uti-
lising agile practices. To perform this tailoring effectively a foundation of a plan driven SDLC was 
needed. This was required as none of the agile methodologies provide comprehensive coverage of all  
the necessary development stages required when developing safety critical software [38]. However, 
Turk [38] does recommended that a safety critical software development project can benefit from 
combining agile techniques with formal plan driven techniques.  The V-Model was chosen as medical 
device software developers are familiar with the V-Model and it produces the necessary outputs re-
quired to achieve regulatory approval and provides guidance for all of the stages of medical device 
software development. Secondly, research was conducted into which agile practices could be inte-
grated into this plan driven SDLC. The agile practices initially selected were identified through the use 
of a literature review. The agile practices and SDLC selected must conform to the regulatory require-
ments whilst still achieving the benefits of tailoring. 
 
 
 
Session I: will be adapted later by the editor 
 
5 − EuroSPI 2012 
 
4.1 Research Methodology 
As part of on-going research into the area of utilising agile practices when developing medical de-
vice software a literature review was conducted. This literature was conducted in accordance with 
Randolph [39]. The literature review began broadly by examining the main software development 
lifecycles being followed in all software development domains. The literature review then focused on 
software development in safety critical industries and then concentrated on software development in 
the medical device domain. Once this part of the literature review was completed, agile methodologies 
were examined. After this examination was completed the focus moved onto the utilisation of agile 
practices when developing safety critical software. When conducting the final phase of the literature 
review a number of seminal papers in the area of using agile practices when developing medical de-
vice software were identified [11, 12, 32-34, 40, 41]. In each case study performed, the organisations 
were initially developing medical device software in accordance with plan driven software development 
lifecycles. Each of the organisations identified the need to embrace agile software development prac-
tices. Consequently upon completion of the implementation of the agile practices each organisation 
found a noticeable improvement in software quality and increased functionality along with reduced 
development costs.  Table 1 presents summarised findings of the literature review and of the seminal 
case studies identified. Table 1 shows the case studies identified and which agile practices each of 
these case studies utilised  
4.2 Integrating Agile Practices with a Plan Driven SDLC 
As stated when developing a mixed method Software Development Life Cycle a foundation is re-
quired. This foundation came in the form of a V-Model for certification proposed by Ge et al. [10]. This 
V-Model differs from the typical V-Model as it includes development stages for “Hazard and Risk Anal-
ysis” and “Regulatory Certification”. These stages are critical which software developed for use in 
medical devices must complete.  
Once the foundation was chosen a method was required to establish which agile practices would 
be merged with the V-Model. The findings of the literature review were used to establish which agile 
practices have so far been successfully implemented when developing medical device software. In 
table 1, a summary of the agile practices suitable for use when developing medical device software 
are outlined. 
Table 1. Case Studies and Agile Practices utilised 
Each of the agile practices used in these case studies were then incorporated into the relevant 
stage of the V-Model. Figure 1 shows the tailored V-Model. This combines the V-Model proposed by 
Ge et al. and the appropriate agile practices as identified through the literature review.  
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Figure 1 V-Model Incorporating Agile Practices 
 
As part of the literature review, agile practices were identified through the key case studies per-
formed. However, none of the key case studies provide information as to which stage of development 
the agile practices were incorporated. Despite this, we have performed a mapping which matched the 
agile practices to the appropriate stage of development, as a number of the practices are more suited 
to specific development stages e.g. Pair Programming = Module Construction and Testing. 
5 Conclusions and Future Work 
In conclusion, research into instances of agile adoption when developing medical device software 
has shown that these projects can benefit from integrating agile practices. Medical device software 
development organisations are bound by regulatory controls. These regulatory controls prevent medi-
cal device organisations from wholly embracing a single agile methodology when developing medical 
device software. The findings of the literature review revealed that there is no SDLC currently availa-
ble which medical device software developers can follow which produces the necessary deliverables 
required to achieve regulatory conformance whilst reaping the benefits of utilising agile practices. Re-
search has been conducted in isolation within organisations such as Medtronic and Cochlear, but no 
evidence exists that suggest the models used in these organisations can be followed with the same 
level of success in other medical device organisations. A common trend also appeared within each of 
these case studies. This trend was that no single agile methodology was appropriate for use when 
developing medical device software and that medical device software development projects benefit 
from a mixed method approach combining agile practices with a plan driven software development 
lifecycle. To this end it becomes apparent that medical device software development organisations 
would greatly benefit from the development of a SDLC that meets both the organisational needs pro-
vided from following a plan driven lifecycle and developmental needs from following agile practices. 
Research conducted as part of this paper will be used as the foundation for the development of a 
tailored V-Model which integrates agile practices which are beneficial to the development of medical 
device software and facilitate the achievement of regulatory compliance. To establish which agile 
practices should be included into the tailored V-Model, every agile practices within each of the agile 
methodologies i.e. Scrum, XP, Test Driven Development, Crystal etc. will be examined to determine 
suitability for use when developing medical device software. Once suitability is determined the appro-
priate practices will be integrated into the tailored V-Model. 
 This tailored V-Model will be developed in collaboration with medical device software organisa-
tions in Ireland. Once the tailored V-Model is completed it will be thoroughly tested by industry. Once 
this model has been finalised the objective is to have a medical device software development project 
fully developed in accordance with the finalised tailored V-Model. 
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